CDK4 and breast carcinoma: Typically reserved for advanced breast cancer following CDK4/6 inhibitor resistance, PI3K-alpha inhibitors have been observed clinically and in cell line data to be ineffective when used in PTEN-null cells (Juric et al., 2015; Costa et al., 2020).